Cellbyte, a Munich-based AI-native platform accelerating pharmaceutical drug launches, has raised $2.75 million in Seed funding.
Investors
The round was led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels.
Frontline Ventures is a specialized European venture capital firm focused on facilitating transatlantic expansion for B2B software companies. It manages two distinct fund strategies: Frontline Seed backs European seed-stage startups when early U.S. traction is critical for hyperscaling; Frontline Growth backs U.S. scaleups at Series B–D stages, when European revenues are essential for IPO readiness.
Cellbyte Use of Funds
The funding will be used to triple headcount, expand engineering capabilities, and accelerate international expansion.
About Cellbyte
Founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, Cellbyte is an AI-native platform that helps pharmaceutical companies launch new drugs worldwide. It streamlines pricing, market access, and regulatory workflows for drug launches by automating data extraction and insight generation, enabling faster and more efficient decision-making across global markets. Headquartered in Munich, Germany, Cellbyte’s goal is to become the leading operating system for commercial pharmaceutical teams worldwide.
Funding Details
Company: Cellbyte GmbH
Raised: $2.75M
Round: Seed
Funding Date: November 2025
Lead Investor: Frontline Ventures
Additional Investors: Y Combinator, Pace Ventures, Saras Capital, Springboard Health Angels
Company Website: https://www.cellbyte.com/
Software Category: Pharmaceutical / Drug Launches
Source: Scott Rosenblum, LEVEL PR